Simcere Pharmaceutical (2096.HK) Q3 2024 Earnings Report

- QQ3 2024 revenue reached 1,760,843,500 CNY, up 9.1% year over year and 13.1% quarter over quarter, reflecting steady top-line momentum as the company continues to monetize its diverse product portfolio in China. The gross margin stood at 81.29%, supporting a constructive profitability framework even as R&D and selling, general & administrative (SG&A) expenses remain elevated due to ongoing pipeline development and market expansion efforts. Net income of 138,282,500 CNY translated to a net margin of 7.85%, with diluted EPS of 0.0545 CNY. EBITDA of 330,756,500 CNY produced an EBITDA margin of 18.78%, underscoring proceeding operating leverage within a high-R&D environment.